Skip to main content
. 2009 Jan 15;338:a2812. doi: 10.1136/bmj.a2812

Table 2.

 Baseline comparisons of intervention (chloramphenicol) and control (paraffin) groups. Values are numbers (percentages) unless stated otherwise

Characteristics Intervention group (n=488) Control group (n=484)
Patients
Mean (SD) age (years) 59.5 (23.2) 59.0 (27.5)
Male 266 (54.5) 262 (54.1)
Smoking status:
 Never smoked 298 (61.1) 299/483 (61.9)
 Ex-smoker 109 (22.3) 108/483 (22.4)
 Current smoker 81 (16.6) 76/483 (15.7)
Diabetes mellitus 37 (7.6) 50/483 (10.4)
With medical condition* 79/478 (16.5) 86/475 (18.1)
Lesions
Body site:
 Neck and face 166 (34.0) 152 (31.4)
 Upper extremities 139 (28.5) 140 (28.9)
 Trunk 108 (22.1) 102 (21.1)
 Lower extremities 75 (15.4) 90 (18.6)
Histology:
 Melanoma and naevi 64 (13.1) 74 (15.3)
 Non-melanoma skin cancer and precursor 350 (71.7) 315 (65.1)
 Other† 74 (15.2) 95 (19.6)
Procedures
Mean (SD) length of excision (mm) 20.9 (25.6) 21.0 (28.8)
Median (interquartile range) No of days until removal of sutures 7 (7-9) 8 (7-10)
With flap 1 (0.2) 3 (0.6)
With two level procedure 4 (0.8) 4 (0.8)

*Chronic obstructive pulmonary disease (n=14), aspirin or clopidogrel (n=120), oral steroids (n=3), continuous inhaled steroids (n=9), warfarin (n=42), ischaemic heart disease (n=7), peripheral vascular disease (n=6), and current cancer (n=21).

†Included seborrhoeic keratosis, re-excisions of melanoma and basal cell carcinoma, sebaceous cyst, epidermal cyst, wart, and dermatitis.